Clarithromycin: Clinical Trials

92 trials of Clarithromycin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

52 completed, 26 unknown, 5 recruiting, 4 not yet recruiting. 92 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 492Completed 52, Unknown 26, Recruiting 5, Not yet recruiting 4, Withdrawn 3, Active not recruiting 1, Suspended 1

Follow Clarithromycin: new trials by email Literature Review of Clarithromycin trials Research Report on Clarithromycin

Trials (filtered) newest first · largest first

All 92 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety of Vonoprazan-Amoxicillin Dual Therapy Versus Concomitant Quadruple Therapy for H. Pylori Eradication
Vonoprazan (Reference), Amoxicillin, Metronidazole - HELICOBACTER PYLORI INFECTIONS
Phase 4RecruitingIgnacio Moratorio1002026-08-052026-11-09
Clinical Trial to Evaluate the Efficacy of Probit-Based Triple Therapy for Helicobacter Pylori Eradication
This study aims to evaluate the efficacy and safety of a 14-day triple therapy regimen consisting of Zastaprazan 20 mg, clarithromycin, and amoxicillin for the eradication of Helicobacter pylori. - Helicobacter Infection
Phase 4Not yet recruitingSamsung Medical Center1032025-12-012025-08-14
Comparison of Two Treatment Regimens of Helicobacter Pylori Infection
Clarithromycin, Levofloxacin - Helicobacter Pylori Infection
Phase 4Not yet recruitingRehman Medical Institute - RMI1562025-12-012025-06-15
Tailored Vs. Empirical Helicobacter Pylori Infection Treatment
Clarithromycin (mutations in the 23S rRNA gene, A2134G, A2142G and A2142C mutations) and levofloxacin resistance (mutations in the gyrA gene) PCR test, Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®), PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days - Helicobacter Pylori Infection
Phase 4Not yet recruitingManuel Coelho da Rocha1602025-09-012024-12-20
Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori Infection
Clarithromycin 500 mg, Amoxicillin 1 g, Omeprazole 40 mg - H Pylori
Phase 4Not yet recruitingRehman Medical Institute - RMI1282025-07-012025-06-27
Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial
Vonoprazan, Tetracycline 500mg tid, Minocycline - Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer
Phase 4RecruitingYongquan Shi4002025-04-012025-08-14
Vonoprazan Evaluation Compared to Standard Triple Therapy in Helicobacter Pylori eRadication
Vonoprazan 20mg, Esomeprazole 40 mg, Amoxicillin 1 g, Clarithromycin 500 mg - Helicobacter Pylori Infection
Phase 4RecruitingAsian Institute of Gastroenterology, India4842025-03-252025-06-11
Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)
Faropenem, Co-amoxiclav, Clarithromycin 500 mg - Pneumonia, Community-Acquired, Bacterial Pneumonia
Phase 4CompletedDr. Md. Alimur Reza1292025-02-202026-08-04
Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment
tegoprazan, Minocycline, bismuth potassium citrate - Helicobacter Pylori Infection Chronic Gastrit
Phase 4Active not recruitingXijing Hospital of Digestive Diseases2082024-11-112025-07-03
Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication
Berberine, Vonoprazan, Amoxicillin - Helicobacter Pylori Infection, Chronic Gastritis
Phase 4CompletedXijing Hospital of Digestive Diseases5582024-09-202025-07-03
Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)
Ceftriaxone 1000 MG, Clarithromycin 500mg, Metronidazole 500 mg - Preterm Premature Rupture of Membrane, Pregnancy, High Risk
Phase 4RecruitingOhio State University562024-07-182026-01-27
Study on the Efficacy and Safety of Berberine, Minocycline, Esomeprazole, and Colloidal Bismuth Quadruple Therapy in the Initial Treatment of Helicobacter Pylori.
esomeprazole, Bismuth, Amoxicillin - Helicobacter Pylori Infection, Chronic Gastritis
Phase 4UnknownXijing Hospital of Digestive Diseases5482023-11-202024-09-19
Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy
Vonoprazan and Amoxicillin, Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole - Helicobacter Pylori Infection
Phase 4CompletedFu Jen Catholic University Hospital3372023-11-142026-02-17
Immunomodulatory Effect of Macrolides in Naturally Occurring Influenza Virus Infections in the Community
Clarithromycin 250 MG, Placebos - Influenza, Human
Phase 4SuspendedThe University of Hong Kong1002023-06-012022-11-04
Efficacy of Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests for Helicobacter Pylori Infection
Rabeprazole, Colloidal Bismuth Pectin Granules, Amoxicillin - Helicobacter Pylori Infection
Phase 4UnknownSecond Affiliated Hospital, Zhejiang University, School of Medicine8552023-03-012023-05-15
Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology
Esomeprazole, Amoxicillin, Bismuth - Gastritis, Dyspepsia
Phase 4CompletedXijing Hospital of Digestive Diseases1242022-12-012025-07-03
Efficacy and Safety of Dual Therapy as First-line Treatment for Hp Infection
Vonoprazan, Rabeprazole, Amoxicillin - Helicobacter Pylori Infection
Phase 4UnknownSecond Affiliated Hospital, Zhejiang University, School of Medicine3932022-08-012023-02-16
Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection
susceptibility-guided tailored therapy (Group A), guidelines-recommended empiric therapy (Group B) - Helicobacter Pylori Infection
Phase 4RecruitingNational Taiwan University Hospital4502022-04-112026-04-15
Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment
Esomeprazole, Bismuth potassium citrate, Metronidazole - Helicobacter Pylori Infection
Phase 4WithdrawnShanghai Zhongshan Hospital2022-03-252026-08-04
Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
Minocycline hydrochloride capsule, Clarithromycin, Amoxicillin - Helicobacter Pylori Eradication
Phase 4UnknownSecond Affiliated Hospital, Zhejiang University, School of Medicine3392022-01-052022-01-13

Showing 20 of 92. Sign in to see all of them.

Conditions studied

Dyspepsia (9)  ·  Peptic Ulcer (9)  ·  Gastritis (7)  ·  Helicobacter Infections (6)  ·  Stomach Neoplasms (3)  ·  Community-Acquired Pneumonia (2)  ·  Pneumonia (2)  ·  cyclopia sequence (2)  ·  Asthma (1)  ·  Borrelia Infections (1)  ·  Chorioamnionitis (1)  ·  Community-Acquired Infections (1)  ·  Crohn Disease (1)  ·  Drug-Related Side Effects and Adverse Reactions (1)  ·  Duodenal Ulcer (1)

Sponsors

Xijing Hospital of Digestive Diseases (9)  ·  Shandong University (7)  ·  Shanghai Jiao Tong University School of Medicine (6)  ·  National Taiwan University Hospital (4)  ·  Mackay Memorial Hospital (3)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (3)  ·  Shanghai Zhongshan Hospital (3)  ·  Damascus Hospital (2)  ·  Kaohsiung Veterans General Hospital. (2)  ·  Kyungpook National University Hospital (2)  ·  Rehman Medical Institute - RMI (2)  ·  The University of Texas Health Science Center at Tyler (2)  ·  Abdul Wali Khan University Mardan (1)  ·  Al-Azhar University (1)  ·  Alexandra Hospital, Athens, Greece (1)

Countries

China (28)  ·  Taiwan (12)  ·  South Korea (5)  ·  United States (4)  ·  Pakistan (3)  ·  Egypt (2)  ·  Greece (2)  ·  Iran (2)  ·  Netherlands (2)  ·  Spain (2)  ·  Syria (2)  ·  Turkey (Türkiye) (2)  ·  Bangladesh (1)  ·  Burma (1)  ·  Denmark (1)

Top investigators

Xiuli Zuo, MD,PhD (5)  ·  Hong Lu, M.D. (4)  ·  Yongquan Shi, Ph. D (4)  ·  Tai-cherng Liou, MD (3)  ·  Li Yanqing, MD, PhD (2)  ·  Taotao Liu, MD (2)  ·  Adrian Canavesi, Endoscopist (1)  ·  Ala' I Sharara, MD (1)  ·  Arnaud Perrier, MD (1)  ·  Bader F Zuberi, FCPS (1)  ·  Bart-Jan Kullberg, Prof., M.D. (1)  ·  Chi-Yang Chang, PhD (1)  ·  Chris J Hawkey (1)  ·  David Y Graham, MD (1)  ·  Dennis KM Ip, MD (1)

Results publications

PMID 32545856, PMID 20947881, PMID 23158886, PMID 23520311, PMID 23562754, PMID 23665990, PMID 25070099, PMID 25286173, PMID 25574111, PMID 25639278, PMID 26338726, PMID 26338825, PMID 26935876, PMID 27028911, PMID 27769562, PMID 27867688, PMID 28266875, PMID 28456631, PMID 28891138, PMID 29082856, PMID 29138921, PMID 30180998, PMID 30635887, PMID 30734357, PMID 30796143, PMID 30893536, PMID 31024299, PMID 31111585, PMID 31523279, PMID 31590634, PMID 31974914, PMID 32428369, PMID 33089598, PMID 34031759, PMID 35164864, PMID 35505308, PMID 36237565, PMID 37361220, PMID 37479526, PMID 38700630, PMID 39924352, PMID 40007457, PMID 40560185, PMID 40844182, PMID 42069497, PMID 42141850, PMID 42595603

NIH funding

2009 (1)